We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Taysha Gene Therapies Inc | NASDAQ:TSHA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.31 | 10.47% | 3.27 | 3.14 | 3.27 | 3.27 | 2.93 | 2.94 | 1,900,709 | 05:00:04 |
Conference Call Details | |
Tuesday, November 14, at 4:30 PM Eastern Time / 3:30 PM Central Time | |
Toll Free: 877-407-0792 | |
International: 201-689-8263 | |
Conference ID: 13741244 | |
Webcast: https://ir.tayshagtx.com/news-events/events-presentations |
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program. Together, we leverage our fully integrated platform with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.
Company Contact:Hayleigh CollinsDirector, Head of Corporate Communications and Investor RelationsTaysha Gene Therapies, Inc.hcollins@tayshagtx.com
Media Contact:Carolyn HawleyCanale Communicationscarolyn.hawley@canalecomm.com
1 Year Taysha Gene Therapies Chart |
1 Month Taysha Gene Therapies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions